Trial Profile
A Phase 1 Safety Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Anti-CD33 CAR-T cell therapy (Primary) ; Cyclophosphamide; Fludarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 24 Oct 2019 Status changed from completed to discontinued.
- 17 Oct 2019 Status changed from active, no longer recruiting to completed.
- 23 Jul 2019 Status changed from recruiting to active, no longer recruiting.